110 related articles for article (PubMed ID: 12890147)
21. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.
Peterson JT; Li H; Dillon L; Bryant JW
Cardiovasc Res; 2000 May; 46(2):307-15. PubMed ID: 10773235
[TBL] [Abstract][Full Text] [Related]
22. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer.
Morán A; Iniesta P; García-Aranda C; De Juan C; Díaz-López A; Sánchez-Pernaute A; Torres AJ; Díaz-Rubio E; Balibrea JL; Benito M
Oncol Rep; 2005 Jan; 13(1):115-20. PubMed ID: 15583811
[TBL] [Abstract][Full Text] [Related]
23. Differential distribution of gelatinases and tissue inhibitor of metalloproteinase-1 in the rat ovary.
Bagavandoss P
J Endocrinol; 1998 Aug; 158(2):221-8. PubMed ID: 9771466
[TBL] [Abstract][Full Text] [Related]
24. The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters.
Giannopoulos G; Pavlakis K; Parasi A; Kavatzas N; Tiniakos D; Karakosta A; Tzanakis N; Peros G
Anticancer Res; 2008; 28(3B):1875-81. PubMed ID: 18630474
[TBL] [Abstract][Full Text] [Related]
25. Role of tissue inhibitors of metalloproteinases (TIMPs) in colorectal carcinoma.
Joo YE; Seo KS; Kim J; Kim HS; Rew JS; Park CS; Kim SJ
J Korean Med Sci; 1999 Aug; 14(4):417-23. PubMed ID: 10485622
[TBL] [Abstract][Full Text] [Related]
26. Identification of matrix metalloproteinases and their tissue inhibitors type 1 and 2 in human masseter muscle.
Singh A; Nelson-Moon ZL; Thomas GJ; Hunt NP; Lewis MP
Arch Oral Biol; 2000 Jun; 45(6):431-40. PubMed ID: 10775672
[TBL] [Abstract][Full Text] [Related]
27. Expression of metalloproteinases (MMP-1, MMP-2, and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in schistosomal portal fibrosis.
Gomez DE; De Lorenzo MS; Alonso DF; Andrade ZA
Am J Trop Med Hyg; 1999 Jul; 61(1):9-13. PubMed ID: 10432047
[TBL] [Abstract][Full Text] [Related]
28. Expression of the metalloproteases MMP-1, MMP-2, MMP-3, MMP-9, MMP-11, TIMP-1 and TIMP-2 in angiocentric midfacial lymphomas.
Meneses-García A; Betancourt AM; Abarca JH; Montes AB; Roa LS; Ruíz-Godoy L
World J Surg Oncol; 2008 Oct; 6():114. PubMed ID: 18954439
[TBL] [Abstract][Full Text] [Related]
29. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N
Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598
[TBL] [Abstract][Full Text] [Related]
30. EMMPRIN (CD 147) is expressed in Hodgkin's lymphoma and anaplastic large cell lymphoma. An immunohistochemical study of 60 cases.
Thorns C; Feller AC; Merz H
Anticancer Res; 2002; 22(4):1983-6. PubMed ID: 12174874
[TBL] [Abstract][Full Text] [Related]
31. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors.
Sogawa K; Kondo K; Fujino H; Takahashi Y; Miyoshi T; Sakiyama S; Mukai K; Monden Y
Cancer; 2003 Nov; 98(9):1822-9. PubMed ID: 14584061
[TBL] [Abstract][Full Text] [Related]
32. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion.
Di Nezza LA; Misajon A; Zhang J; Jobling T; Quinn MA; Ostör AG; Nie G; Lopata A; Salamonsen LA
Cancer; 2002 Mar; 94(5):1466-75. PubMed ID: 11920503
[TBL] [Abstract][Full Text] [Related]
33. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer.
McCarthy K; Maguire T; McGreal G; McDermott E; O'Higgins N; Duffy MJ
Int J Cancer; 1999 Feb; 84(1):44-8. PubMed ID: 9988231
[TBL] [Abstract][Full Text] [Related]
34. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition.
Li H; Simon H; Bocan TM; Peterson JT
Cardiovasc Res; 2000 May; 46(2):298-306. PubMed ID: 10773234
[TBL] [Abstract][Full Text] [Related]
35. Expression of MMP-9, TIMP-1, CD-34 and factor-8 as prognostic markers for squamous cell carcinoma of the tongue.
Guttman D; Stern Y; Shpitzer T; Ulanovski D; Druzd T; Feinmesser R
Oral Oncol; 2004 Sep; 40(8):798-803. PubMed ID: 15288834
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinases in mild and severe temporomandibular joint internal derangement synovial fluid.
Srinivas R; Sorsa T; Tjäderhane L; Niemi E; Raustia A; Pernu H; Teronen O; Salo T
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 May; 91(5):517-25. PubMed ID: 11346728
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of immunophenotype in aggressive non-Hodgkin's lymphoma.
Tsartsidze E; Betaneli M
Georgian Med News; 2006 May; (134):107-9. PubMed ID: 16783081
[TBL] [Abstract][Full Text] [Related]
38. [Correlation between matrix metalloproteinases-2 and tissue inhibitor of metalloproteinase-2 expression, metastatic potential and tumor angiogenesis in synovial sarcoma and its prognostic significance].
Sun BC; Sun Y; Zhao XL; Wang J; Wang X; Liu YX
Zhonghua Bing Li Xue Za Zhi; 2006 Mar; 35(3):155-8. PubMed ID: 16630504
[TBL] [Abstract][Full Text] [Related]
39. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein.
Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
Clin Cancer Res; 2005 May; 11(9):3257-64. PubMed ID: 15867221
[TBL] [Abstract][Full Text] [Related]
40. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.
Goldbach-Mansky R; Lee JM; Hoxworth JM; Smith D; Duray P; Schumacher RH; Yarboro CH; Klippel J; Kleiner D; El-Gabalawy HS
Arthritis Res; 2000; 2(2):145-53. PubMed ID: 11062605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]